San Diego-based Viking Therapeutics marked alone as a serious competitor in the weight loss drug market place in February just after revealing promising facts from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection As well as in March the company un